

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**Interventional procedure consultation document**

**Transcutaneous stimulation of the cervical  
branch of the vagus nerve for cluster  
headache and migraine**

Cluster headaches are attacks of severe pain on one side of the head, usually around the eye. Other symptoms include a red and watery eye and a runny nose. They can happen several times a day and last from minutes to hours.

Migraines are severe headaches, usually felt as a throbbing pain at the front or side of the head, which can be accompanied by nausea and sensitivity to light. They may last for several hours.

In this procedure, the patient uses a small handheld device to stimulate nerves on the side of their neck with the aim of relieving pain and reducing the number of headache attacks.

The National Institute for Health and Care Excellence (NICE) is examining transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine and will publish guidance on its safety and efficacy to the NHS. NICE's Interventional Procedures Advisory Committee has considered the available evidence and the views of specialist advisers, who are consultants with knowledge of the procedure. The Advisory Committee has made provisional recommendations about transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine.

This document summarises the procedure and sets out the provisional recommendations made by the Advisory Committee. It has been prepared for public consultation. The Advisory Committee particularly welcomes:

- comments on the provisional recommendations
- the identification of factual inaccuracies
- additional relevant evidence, with bibliographic references where possible.

**Note that this document is not NICE's formal guidance on this procedure. The recommendations are provisional and may change after consultation.**

The process that NICE will follow after the consultation period ends is as follows.

- The Advisory Committee will meet again to consider the original evidence and its provisional recommendations in the light of the comments received during consultation.
- The Advisory Committee will then prepare draft guidance which will be the basis for NICE's guidance on the use of the procedure in the NHS.

For further details, see the [Interventional Procedures Programme process guide](#), which is available from the NICE website.

Through its guidance NICE is committed to promoting race and disability equality, equality between men and women, and to eliminating all forms of discrimination. One of the ways we do this is by trying to involve as wide a range of people and interest groups as possible in the development of our interventional procedures guidance. In particular, we aim to encourage people and organisations from groups who might not normally comment on our guidance to do so.

In order to help us promote equality through our guidance, we should be grateful if you would consider the following question:

Are there any issues that require special attention in light of NICE's duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations between people with a characteristic protected by the equalities legislation and others?

Please note that NICE reserves the right to summarise and edit comments received during consultations or not to publish them at all where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would otherwise be inappropriate.

Closing date for comments: Friday 18 December 2015

Target date for publication of guidance: March 2016

## **1 Provisional recommendations**

- 1.1 Current evidence on the safety of transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine raises no major concerns. The evidence on efficacy is

IPCD: Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine

limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent and audit or research.

1.2 Clinicians wishing to do transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine should:

- Inform the clinical governance leads in their NHS trusts.
- Ensure that patients understand the uncertainty about the procedure's efficacy and provide them with clear written information. In addition, the use of NICE's [information for the public](#) *[[URL to be added at publication]]* is recommended.
- [Audit](#) *[[URL to audit tool to be added at publication]]* and review clinical outcomes of all patients having transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (see section 7.2).

1.3 NICE encourages further research on transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine. Studies should describe whether it is used for treatment or prevention, and whether it is used for cluster headache or migraine. Clinicians should clearly document details of patient selection and the treatment regimen. Outcome measures should include changes in the number and severity of cluster headache or migraine episodes, medication use, quality of life in the short and long term, side effects, acceptability, and device durability. NICE may update this guidance on publication of further evidence.

## **2 Indications and current treatments**

- 2.1 Cluster headaches are characterised by episodes of unilateral periorbital pain, conjunctival injection, lacrimation and rhinorrhoea. Attacks can last from a few minutes to several hours and can occur many times a day, over several days. Migraines are severe headaches, often accompanied by nausea, photophobia and phonophobia. In some people, migraines may be accompanied by aura which is characterised by the perception of flashing lights, the perception of unpleasant odours, confusion or difficulty speaking.
- 2.2 The usual treatment option for patients with cluster headache or migraine is medical therapy, either to prevent or stop acute attacks. Medical treatments for acute cluster headache attacks include oxygen inhalation and medications such as triptans. Corticosteroids and verapamil may be used to prevent or reduce the frequency of cluster headaches. Medical treatments for acute migraine attacks include analgesics, triptans and anti-emetics. Beta-blockers, tricyclic antibiotics, pizotifen and anticonvulsants may be used to prevent or reduce the frequency of migraine attacks.
- 2.3 Surgical treatments are reserved for patients with distressing symptoms that are refractory to medical treatments. For patients with chronic cluster headache, surgical treatments include deep brain stimulation to modulate central processing of pain signals, and radiofrequency ablation to interrupt trigeminal sensory or autonomic pathways. For patients with chronic migraine, surgical treatments include occipital nerve blocks and occipital nerve stimulation.

### 3 The procedure

- 3.1 Transcutaneous vagus nerve stimulation uses low voltage electrical currents to stimulate the cervical branch of the vagus nerve. The aim is to relieve pain and reduce the frequency of attacks for both cluster headaches and migraine.
- 3.2 Therapy is self-administered by the patient, using a handheld device the size of a mobile phone. The patient places the device on the side of the neck, over the cervical branch of the vagus nerve, positioning its 2 smooth metal stimulation surfaces in front of the sternocleidomastoid muscle, over the carotid artery. The patient slowly increases the stimulation strength until small muscle contractions are felt under the skin; stimulation is then applied for approximately 90 seconds. The device can be used to treat acute attacks, and as prophylaxis between attacks.

### 4 Efficacy

This section describes efficacy outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the [interventional procedure overview](#) [add URL].

#### ***Efficacy of transcutaneous stimulation of the cervical branch of the vagus nerve for treating cluster headache***

- 4.1 In a randomised controlled trial of 97 patients with cluster headache treated by standard care plus transcutaneous vagus nerve stimulation (tVNS; n=48) or standard care alone (n=49), the mean number of cluster headache attacks per week decreased by 5.9 attacks in the standard care plus tVNS group and by 2.1 attacks

in the standard care alone group at 4-week follow-up (p value between groups=0.02). Baseline measurements were not reported. During the extension phase of the study, patients from both groups received adjunctive tVNS for 4 additional weeks. In this period, the mean number of cluster headache attacks per week decreased from 9.6 to 7.6 in patients who were initially in the standard care plus tVNS group (n=30; p<0.001) and from 15.7 to 12.4 in patients initially in the standard care alone group (n=41; p<0.001).

- 4.2 In a case series of 19 patients with cluster headache, complete resolution of pain was achieved in 47% of cluster headache attacks within a mean of 11 minutes of starting neurostimulation.
- 4.3 In the randomised controlled trial of 97 patients with cluster headache treated by standard care plus tVNS or standard care alone, the mean number of times subcutaneous sumatriptan was used decreased from 7.2 to 2.8 in the standard care plus tVNS group (n=32; p=0.007) and increased from 6.8 to 7.5 in the standard care alone group (n=42; not significant), during the last 2 weeks of a 4-week follow-up period. In the same study, the mean number of times inhaled oxygen was used decreased from 17.3 to 6.5 in the standard care plus tVNS group (n=32; p=0.02) and from 12.6 to 10.8 in the standard care alone group (n=42; not significant) during the last 2 weeks of a 4-week follow-up period.
- 4.4 In the randomised controlled trial of 97 patients with cluster headache treated by standard care plus tVNS or standard care alone, mean EQ-5D scores (ranging from 0 to 100 with higher scores indicating better quality of life) increased from baseline by 9.20 and 0.27 points respectively at 4-week follow-up (p=0.039). During the extension phase of the study, patients from both groups

received adjunctive tVNS for 4 additional weeks. In this period, mean EQ-5D scores increased from baseline by 10.79 points in patients who were initially in the standard care plus tVNS group and 4.36 points in patients initially in the standard care alone group (p value not reported).

### ***Efficacy of transcutaneous stimulation of the cervical branch of the vagus nerve for treating migraine***

- 4.5 In a case series of 50 patients with high-frequency episodic migraine or chronic migraine, pain relief (defined as more than a 50% improvement in visual analogue scale scores for pain) was reported in 38% (50/131) of attacks, 1 hour after neurostimulation. Complete resolution of pain was reported in 18% (23/131) of attacks, 1 hour after neurostimulation. Pain relief and complete resolution of pain were reported in 51% (67/131) and 23% (30/131) of attacks, respectively, 2 hours after neurostimulation.
- 4.6 In a case series of 30 patients with migraine, relief of nausea was reported in 38% (11/29) of attacks which were accompanied by nausea. In the same study, relief of photophobia was reported in 30% (16/53) of attacks which were accompanied by photophobia. Relief of phonophobia was reported in 52% (17/33) of attacks which were accompanied by phonophobia.
- 4.7 In the case series of 50 patients with high-frequency episodic migraine or chronic migraine, complete recovery from functional disability was reported in 35% (46/131) of attacks 2 hours after neurostimulation.

- 4.8 In the case series of 50 patients with high-frequency episodic migraine or chronic migraine, rescue medication was needed in 53% (70/131) of attacks 2 hours after neurostimulation.
- 4.9 Specialist advisers listed key efficacy outcomes as complete resolution of pain, reduction in the frequency, duration and severity of headache episodes, use of rescue medication, and improvements in quality of life.

## 5 Safety

This section describes safety outcomes from the published literature that the Committee considered as part of the evidence about this procedure. For more detailed information on the evidence, see the [interventional procedure overview](#) *[add URL]*.

- 5.1 In a randomised controlled trial of 97 patients with cluster headache transcutaneous vagus nerve stimulation (tVNS) was judged to cause cluster headache in 2% (1/48) of patients in the standard care plus tVNS group and 10% (5/49) of patients initially in the standard care alone group but who then received adjunctive tVNS in a 4-week extension phase. In the same study, headaches that were not cluster headaches were reported in 8% (4/48) of patients in the standard care plus tVNS group and 2% (1/49) of patients initially in the standard care alone group.
- 5.2 Dizziness was reported in 6% (3/48) of patients in the standard care plus tVNS group and 6% (3/49) of patients in the standard care alone group in the randomised controlled trial of 97 patients with chronic cluster headache (no further details on timing in relation to tVNS provided).



- 5.3 Oropharyngeal pain was reported in 6% (3/48) of patients in the standard care plus tVNS group and 2% (1/49) of patients in the standard care alone group in the randomised controlled trial of 97 patients with chronic cluster headache.
- 5.4 Moderate shoulder pain or spasm was reported in 7% (2/28) of patients in a case series of 30 patients with migraine (no further details on timing in relation to tVNS provided).
- 5.5 Mild lip or facial drooping was reported in 7% (2/28) of patients in the case series of 30 patients with migraine (no further details on timing in relation to tVNS provided).
- 5.6 Neck stiffness was reported in 18% (5/28) of patients in the case series of 30 patients with migraine (no further details on timing in relation to tVNS provided).
- 5.7 Reddening of the skin around the treatment site was reported in 7% (2/28) of patients in the case series of 30 patients with migraine.
- 5.8 In the randomised controlled trial of 97 patients with chronic cluster headache treated by standard care plus tVNS or standard care alone, 1 or more of the following device-related adverse events were reported in 27% (13/48) of patients in the standard care plus tVNS group: depressed mood, malaise, oropharyngeal pain, induced cluster headache, muscle twitching, muscle spasms, hot flushes, acne, pain, throat tightness, dizziness, hyperhidrosis, toothache, decreased appetite and skin irritation. One or more of the following device-related adverse events were reported in 14% (7/49) of patients initially in the standard care alone group: erythema, facial oedema, induced cluster headache, chest pain, fatigue, depressed mood, pruritus, musculoskeletal stiffness and

parosmia. All adverse events occurred during the extension phase of the study when these patients received adjunctive tVNS.

- 5.9 A single occurrence of the following adverse events was reported in the case series of 30 patients with migraine: mild confusion that lasted for 2 hours after neurostimulation, joint pain, mild twitching of neck muscles, mild swelling of the neck, tinnitus in 1 ear, fever (39°C), a raspy voice, fatigue, coughing and sneezing.
- 5.10 Palpitations were reported in 1 patient in a case series (conference abstract) of 18 patients with various primary headache disorders. In the same study, tonic muscle contraction was reported in 17% (3/18) of patients and cervical muscle spasm was reported in 1 patient.
- 5.11 In addition to safety outcomes reported in the literature, specialist advisers are asked about anecdotal adverse events (events which they have heard about) and about theoretical adverse events (events which they think might possibly occur, even if they have never done so). For this procedure, specialist advisers listed the following anecdotal adverse events: shortness of breath and changes in blood pressure. They considered that cardiac arrhythmia and interaction with pacemaker devices were theoretical adverse events.

## **6 Committee comments**

- 6.1 The Committee noted that cluster headache and migraine are very common conditions and therefore good evidence of efficacy is particularly important. This consideration contributed to the recommendation for further research.

- 6.2 In its interpretation of the evidence, the Committee noted the potential for a placebo response and the relapsing and remitting course of cluster headaches and migraine.
- 6.3 The Committee noted that further evidence is likely to become available from a number of current trials.
- 6.4 The Committee noted patient commentary, much of which was favourable.

## **7 Further information**

- 7.1 For related NICE guidance, see the [NICE website](#).
- 7.2 This guidance requires that clinicians doing the procedure make special arrangements for audit. NICE has identified relevant audit criteria and is developing an audit tool (which is for use at local discretion). This tool will be available when the guidance is published.

Bruce Campbell

Chairman, Interventional Procedures Advisory Committee

November, 2015